Reborn TPP could see vital subsidised drugs cost more

By Peter Martin
Updated November 9 2017 - 10:49am, first published November 8 2017 - 6:56pm

Talks aimed at reviving the stalled Trans-Pacific Partnership between Australia and 10 other nations could add as much as $100 million to the cost of the Pharmaceutical Benefits Scheme a new study has found.

Get the latest St George news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.